Improving early phase oncology clinical trial design: An opportunity for statisticians

Authors: Phillips, A. and Mondal, S.

Journal: Pharmaceutical Statistics

Volume: 22

Issue: 3

Pages: 577-580

eISSN: 1539-1612

ISSN: 1539-1604

DOI: 10.1002/pst.2287

Abstract:

This short communication supports that rule-based study designs such as the ‘3 + 3’ study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.

Source: Scopus

Improving early phase oncology clinical trial design: An opportunity for statisticians.

Authors: Phillips, A. and Mondal, S.

Journal: Pharm Stat

Volume: 22

Issue: 3

Pages: 577-580

eISSN: 1539-1612

DOI: 10.1002/pst.2287

Abstract:

This short communication supports that rule-based study designs such as the '3 + 3' study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.

Source: PubMed

Improving early phase oncology clinical trial design: An opportunity for statisticians

Authors: Phillips, A. and Mondal, S.

Journal: PHARMACEUTICAL STATISTICS

Volume: 22

Issue: 3

Pages: 577-580

eISSN: 1539-1612

ISSN: 1539-1604

DOI: 10.1002/pst.2287

Source: Web of Science (Lite)

Improving early phase oncology clinical trial design: An opportunity for statisticians.

Authors: Phillips, A. and Mondal, S.

Journal: Pharmaceutical statistics

Volume: 22

Issue: 3

Pages: 577-580

eISSN: 1539-1612

ISSN: 1539-1604

DOI: 10.1002/pst.2287

Abstract:

This short communication supports that rule-based study designs such as the '3 + 3' study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.

Source: Europe PubMed Central